Pharmaceuticals: Paris NASH meeting feedback
PharmaceuticalsParis NASH meeting feedback
GLP-1 analogs ok for NASH but not DPP-IV or SGLT2 inhibitors
ALT reduction and "metabolic" components are key
Some words about the interest of PPARα/δ
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.